- Home
- MPB vs PCRX Comparison
MPB vs PCRX Comparison
Compare MPB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PCRX
- Stock Information
- Founded
- MPB 1868
- PCRX 2006
- Country
- MPB United States
- PCRX United States
- Employees
- MPB N/A
- PCRX N/A
- Industry
- MPB Major Banks
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PCRX Health Care
- Exchange
- MPB Nasdaq
- PCRX Nasdaq
- Market Cap
- MPB 641.4M
- PCRX 1.2B
- IPO Year
- MPB N/A
- PCRX 2011
- Fundamental
- Price
- MPB $29.21
- PCRX $22.90
- Analyst Decision
- MPB Buy
- PCRX Buy
- Analyst Count
- MPB 2
- PCRX 8
- Target Price
- MPB $36.00
- PCRX $28.38
- AVG Volume (30 Days)
- MPB 107.3K
- PCRX 545.0K
- Earning Date
- MPB 07-23-2025
- PCRX 07-29-2025
- Dividend Yield
- MPB 2.70%
- PCRX N/A
- EPS Growth
- MPB 23.94
- PCRX N/A
- EPS
- MPB 2.88
- PCRX N/A
- Revenue
- MPB $181,865,000.00
- PCRX $702,772,000.00
- Revenue This Year
- MPB $24.31
- PCRX $7.54
- Revenue Next Year
- MPB $13.74
- PCRX $10.78
- P/E Ratio
- MPB $10.28
- PCRX N/A
- Revenue Growth
- MPB 9.21
- PCRX 3.08
- 52 Week Low
- MPB $22.50
- PCRX $11.16
- 52 Week High
- MPB $33.87
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- MPB 61.31
- PCRX 35.82
- Support Level
- MPB $29.03
- PCRX $22.82
- Resistance Level
- MPB $30.00
- PCRX $23.83
- Average True Range (ATR)
- MPB 0.63
- PCRX 0.74
- MACD
- MPB 0.14
- PCRX -0.02
- Stochastic Oscillator
- MPB 68.11
- PCRX 6.22
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.